Obesity Pipeline Viking Therapeutics is advancing VK2735 with both injectable (Phase 3) and oral formulations for obesity, indicating strong potential for partnerships or licensing in weight management markets and related metabolic comorbidities.

Viral Lipid Metabolism VK2809, a thyroid receptor beta agonist, has shown favorable Phase 2b results in NASH and fibrosis and LDL-C reductions, presenting opportunities for collaborations with liver disease and cardiovascular focused partners.

DACRA Programs New internal DACRA series targeting obesity and metabolic disorders opens doors for co-development or strategic alliances with companies focused on dual amylin and calcitonin receptor pathways.

Rare Disease Focus VK0214 demonstrates activity in X-linked adrenoleukodystrophy and related ALD conditions, suggesting potential to engage rare disease specialists or patient access programs and niche pharma partnerships.

Financial & Scale With a mid-size team and substantial funding and revenue, Viking is positioned to pursue multiple parallel trials and partnerships in metabolic and liver diseases, enabling capacity for licensing deals or joint ventures to expand reach.